Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)

Inclusion Criteria: * Advanced or metastatic hepatocellular carcinoma (HCC) not suitable for surgery or various loco-regional therapies. * Diagnosis of HCC confirmed either by cyto-histological confirmation or by non-invasive criteria according to the European Association for Study of Liver disease (EASL) criteria. * Child-Pugh A or B7 cirrhosis. * Eastern Co-Operative Group (ECOG) performance status ≤ 2. * Life expectancy of ≥ 12 weeks. * Adequate organ function (blood transfusion or use of biologic response modifiers is not permitted). * Measurable disease with at least one lesion, which is at least 1 cm in one dimension on computed tomography (CT) or magnetic resonance imaging (MRI). * Able and willing to meet all protocol-required treatments, investigations and visits. * Signed written informed consent form. Exclusion Criteria: * Prior systemic therapy for advanced HCC. * Central nervous system (CNS) metastasis. * History of liver transplantation. * Peripheral sensory neuropathy with functional impairment before the first cycle of treatment. * History of cardiac disease. * Uncontrolled hypertension. * Women who are pregnant or breast-feeding, or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception. * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.